Case of COVID-19 infection-induced complement-mediated thrombotic microangiopathy

The SARS-CoV-2 virus can cause thrombotic microangiopathy (TMA) by alternate pathway activation. We present a case of a young female patient who presented with fever and dialysis-dependent acute kidney injury. On evaluation, she was diagnosed with COVID-19-induced complement-mediated thrombotic microangiopathy (CM-TMA). She was initially managed with plasma exchange (PLEX). However, because of poor response to PLEX, she was administered Inj Eculizumab. She became dialysis independent and had normal renal function on follow-up visits.